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errors in clinical practice, using the Addenbrooke’s Cognitive Examination-III (ACE-III), and then
the reduction in error rate using a computerized alternative, the ACEmobile app.
Methods: In study 1, we evaluated ACE-III assessments completed in National Health Service
(NHS) clinics (n 5 87) for administrator error. In study 2, ACEmobile and ACE-III were then eval-
uated for their ability to capture accurate measurement.
Results: In study 1, 78% of clinically administered ACE-IIIs were either scored incorrectly or had
arithmetical errors. In study 2, error rates seen in the ACE-III were reduced by 85%–93% using ACE-
mobile.
Discussion: Error rates are ubiquitous in routine clinical use of cognitive screening tests and the
ACE-III. ACEmobile provides a framework for supporting reduced administration, scoring, and
arithmetical error during cognitive screening.
 2017 Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords: Screening assessment; Cognitive assessment; Alzheimer’s; Dementia; Computerized; App; Usability; Validity;Administrator error1. Introduction
The psychometric properties of cognitive screening tools
for dementia are routinely reported, yet far less is known
about the clinician’s ability to administer and score these
tests accurately. Evidence suggests that users make many
more errors than expected [1–3]. There is surprisingly
little detail in the literature on how well the cognitivedeclared that no conflict of interest exists.
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blished by Elsevier Inc. on behalf of the Alzheimer’s Associ
licenses/by-nc-nd/4.0/).screening tests perform in the hands of the clinicians for
whom they are designed.
Despite the brevity and perceived simplicity of two of
the most commonly used cognitive assessment instruments
in the United Kingdom—the Mini–Mental State Exa-
mination [4] and the Addenbrooke’s Cognitive Exa-
mination–Revised (ACE-R) [5]—test scoring simulation
studies have revealed high rates of errors on both measures
[6,7]. Both theMini–Mental State Examination and ACE-R
use cutoffs for determining caseness, and this influences
subsequent diagnostic/treatment pathways, highlighting
the importance of accurate assessment.ation. This is an open access article under the CC BY-NC-ND license (http://
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the potential to improve the standards of administration,
scoring, and reporting, as by automating processes, the pos-
sibility of human error is reduced. For example, it is possible
to more closely control administration instructions, thus
reducing the chance of intrarater and interrater variation.
The scoring of a test can also be supported or automated,
reducing the chance of arithmetical errors.
The use of a product in real-world settings cannot be pre-
sumed andmust be tested. Such usability research is a world-
wide standard in medical device evaluation [8–10] but until
recently has been largely neglected in the validation of
cognitive screening assessments. Furthermore, there are
few studies that have evaluated the use of these tools in
routine clinical practice.
The present study set out to explore the nature of scoring
errors using the ACE-III in routine National Health Service
(NHS) practice. This was followed by a comparison of the
ACE-III and ACEmobile, a new iPad-based version developed
by the authors. The aimwas to assess the ability of each tool to
support a clinician to capture accurate measurement, that is,
the hypothetical score that the patient would receive with
zero measurement error. ACEmobile was designed to support
users of the ACE-III by guiding and automating the adminis-
tration, rule adherence, scoring, and reporting.
1.1. Aims and hypotheses
Aim 1: To establish the presence, nature, and extent of
scoring errors on the ACE-III in standard clinical prac-
tice, via the analysis of completed ACE-III assessments
from NHS memory assessments (study 1).
Hypothesis 1: High rates of administration and arith-
metical errors will be observed in ACE-III assessments
from NHS memory clinics.
Aim 2: To compare the measurement accuracy of ACE-III
and ACEmobile (study 2).
Hypothesis 2: Administration and reporting errors will be
significantly less for ACEmobile than for ACE-III.2. Study 1: Identification of scoring errors on the ACE-III
in standard NHS clinical practice
2.1. Sample
ACE-III scoresheets (N 5 132) were extracted from the
electronic patient records of four Older People’s Community
Mental Health teams in Devon, UK (with NHS ethical
approval). Of these, 45 (34%) were subsequently excluded
from the analysis because they were not suitable for further
analysis (i.e., incomplete assessments, scores omitted, illeg-
ible, and older version of ACE used [i.e., ACE-R]). A total
of 87 ACE-III scoresheets were subsequently analyzed. The
ACE-IIIs were administered by community psychiatric nurses
(63%, n5 55), psychiatrists (26%, n5 23), and occupational
therapists (10%,n5 9).Details of specific trainingundertakenby each administrator were not collected but were assumed to
be the standard required for that clinical service. This was
deemed to be representative of standardNHS clinical practice.
2.2. Measures
The ACE-III is a cognitive screening tool to detect mild
dementia and distinguish between Alzheimer’s disease and
frontotemporal dementia [11]. It contains 24 individual test
items contributing to five subdomains—attention (18 points),
memory (26 points), fluency (14 points), language (26 points),
and visuospatial functioning (16 points), with a total score of
100. The ACE-III shows high sensitivity and specificity for
dementia using a cutoff of 88 or 82, respectively [12].
2.3. Procedure
Two anonymized copies of each ACE-III were produced.
Rescoring was conducted by two raters, strictly following
the published scoring guidelines. The two data sets were
compared for consistency using an Excel formula. There
were 121 discrepancies between raters, equating to an error
rate of 2.58%. The second author adjudicated on the dis-
crepancies to reconcile the differences and produce a single
data set with an accurate score at the individual item level,
subdomain level, and ACE-III total score.
Data were double entered, and any discrepancies were
adjudicated by the lead researcher. Finalized ACE-IIIs were
then compared back to the clinician-scored ACE-IIIs. Scoring
errors (points deducted or added in error by each clinician, for
each subtest), arithmetic errors (mental arithmetic errors
made in adding the scores together), and total error (scoring
and arithmetic errors combined) were calculated.
2.4. Results
The range of clinician ACE-III total scores in the sample
was from 30 to 88 points (mx 5 64.80, SD 5 13.24).
Scoring errors were observed in 68% of the ACE-IIIs.
Arithmetic errors were observed in 24% of ACE-IIIs, with
a range of 210 to 10. Only 22% of ACE-IIIs had no errors
at all. The total error rate ranged from 0 to 22, with a
mean of 3.3 (SD5 4.2). In 22% of the sample, the total error
rate was 5 or more points (Fig. 1).
At the subdomain level, 46% and 44.8% of clinicians
made at least one error on the visuospatial and language do-
mains, respectively. Errors were present but observed less
frequently for the memory (20%), fluency (15%), and atten-
tion and orientation (12%) domains. At the individual item
level, 39% of clinicians made at least one error on sentences,
34% on clock drawing, and 11% on animal fluency.
2.5. Summary
In NHS settings, clinician errors in scoring, mental arith-
metic, and reporting theACE-III were commonplace. Howev-
er, this is likely to be an underestimate of the error rate because
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wrong verbal instructions, incorrectly prompting, not
following the rules in themanual). This is addressed in study 2.3. Study 2: Usability study—Evaluation of ACEmobile
versus ACE-III, on a user’s ability to accurately measure
cognitive functioning
3.1. Sample
According to usability research methodology [13], to
capture 94% of user errors, a sample size of 10 per group
was required (assuming 25% of users demonstrate errors).
This number was considered more than adequate, given
the high rates of scoring errors observed in study 1.
The sample included trainee clinical psychologists
(trainees) and PhD/postgraduate health science students. Par-
ticipants were recruited during training sessions and randomly
allocated to an ACE-III or ACEmobile group. The ACE-III
group (N 5 10 mean age 25) included five trainees and five
postgraduates, and the ACEmobile group (N 5 11, mean
age 27) included six trainees and five postgraduates. Of these,
one ACEmobile participant and three ACE-III participants re-
ported previous experience using ACE-III in a clinic setting.3.2. Procedure
The ACE-III group was asked to read the ACE-III admin-
istrationmanual alongside the test sheets. This was considered
the minimal training requirement that could be expected for a
new user of the ACE-III. The ACEmobile group was asked to
complete the in-App automated training module.
Using data from study 1, a mock patient script was gener-
ated that would test the rater’s accuracy of administration,
scoring, and reporting of the test. This script was used by the
experimenter in the role of a mock patient. The development
of the script was informed by patient responses and scoring er-
rors from study 1. The mock patient’s total score was 1 point
below the mean ACE-III score in study 1 (i.e., 64/100).Fig. 1. Histogram showing the frequency of total errors in 87 ACE-IIIs from
NHS Older People’s Mental Health teams. Abbreviations: ACE-III, Adden-
brooke’s Cognitive Examination-III; NHS, National Health Service.Participants were instructed to complete their assessment
as if they were “working in a memory clinic.” Participants
were instructed to prioritize accuracy over time. Participants
in the ACE-III group were allowed access to the admin-
istration manual throughout.3.3. Data preparation
Inspection of the data revealed that 90% of ACE-III and
75% of ACEmobile participants scored the cube subtest
incorrectly, making the same error (awarding 1 point rather
than 0). It was later considered that the cube drawn by the
mock patient was not representative of a likely dementia per-
formance and was too difficult to match with the scoring
criteria. These data were considered an artifact of the exper-
imental design, and so in the following analysis, all parti-
cipants were credited with a correct score.3.4. Results
Table 1 summarizes the difference between ACEmobile
and ACE-III scoring accuracy. The table provides sum-
maries of ACE-III “total error” comprising administration,
scoring, and arithmetic errors. The ACEmobile “total error”
is the sum of administration and scoring errors only as the
arithmetic component of the measure is automated and
computerized.
3.4.1. Administration/scoring errors
The total error rate between the ACEmobile group
(mx 5 1.5 points) and the ACE-III group (mx 5 7.4 points)
revealed significantly more errors in the ACE-III group
[U(19) 5 7, Z 5 23.3, P , .01]. The range of total errors
was large for the ACE-III group, ranging from 2 to 16 points.
3.4.2. Arithmetic scoring errors
For the total reported scores, none of the participants in
the ACE-III group summed up correctly. The mean arith-
metic error rate was 24.1 points (SD 5 5.2) with a range
of 1 to 212 points.
Comparison of errors made within each subdomain is
shown in Table 2.
For the ACE-III group, errors were observed across all
domains. Errors for ACEmobile were mostly in the language
domain, in particular, the naming task (44%, N 5 7) and
reading task (19%, N 5 3). A usability issue was observed
for the naming task, which is discussed below.
3.4.3. Time to complete assessments
Assessment time, from initiation to final reported score,
was on average 26 minutes in the ACE-III group
(SD 5 6.2) and 21 minutes in the ACEmobile group
(SD 5 2.5). This was a significant difference favoring the
ACEmobile group (t value 2.20; P , .05). This includes
arithmetic calculation time for the ACE-III, which was not
required by ACEmobile.
Table 1
Scoring accuracy for ACEmobile and ACE-III, with and without arithmetic errors (excluding cube scoring)
ACEmobile (n 5 11)
Administration/scoring
errors (mean [SD], range)
ACE-III (n 5 10)
Administration/scoring
errors (mean [SD], range)
ACE-III (n 5 10)
Administration plus arithmetic
errors (mean [SD], range)
Total scoring errors per rater 1.5 (1.6), 0–4 7.7 (3.9)*, 2–16 10.3 (4.8)*, 4–20
Abbreviations: ACE-III, Addenbrooke’s Cognitive Examination-III; SD, standard deviation.
NOTE. Arithmetic errors for ACEmobile are zero as this step is automated.
*Significant difference compared to ACEmobile performance, P , .01.
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The naming task accounted for 44% of ACEmobile
administration/scoring errors. A significant proportion
(35%) of the group showed similar errors on the first few
items of this subtest, seemingly reflecting a usability error
with the App that was self-corrected by all participants (it
is not clear which side of the screen to tap for “correct”
and “incorrect,” and they were not given a prompt until after
tapping). Adjusting for the usability errors by removing the
incorrect naming items reduced the distance from the correct
score from amean of 2.5 to 0.6. The revised scorewas signif-
icantly different from the ACE-III group [U(19) 5 10.5,Table 2
Summary of domain and sub-domain errors on ACE-III and ACEmobile
Domain Subtest
ACE-III
percentage
of total errors
(number
of errors)
ACEmobile
percentage
of total errors
(number
of errors)
Orientation/attention Orient 1 6 (5) 0 (0)
Orient 2 1 (1) 0 (0)
Registration 1 (1) 13 (2)
Attention 14 (11) 0 (0)
Domain total 23 (18) 13 (2)
Visuospatial Infinity 0 (0) 0 (0)
Clock 4 (3) 0 (0)
Dots 6 (5) 6 (1)
Frag letters 0 (0) 0 (0)
Domain total 10 (8) 6 (1)
Memory LKB recall 0 (0) 0 (0)
Anterograde 5 (4) 0 (0)
Retrograde 1 (1) 0 (0)
Delayed 5 (4) 0 (0)
Recog 17 (13) 0 (0)
Domain total 29 (22) 0 (0)
Language Comprehension 5 (4) 6 (1)
Writing 4 (3) 6 (1)
Word repetition 5 (4) 6 (1)
Phrase repetition 1 (1) 0 (0)
Naming 5 (4) 44 (7)
Comprehension pics 5 (4) 0 (0)
Reading 1 (1) 19 (3)
Domain total 27 (21) 81 (13)
Fluency Phonetic 4 (3) 0 (0)
Semantic 6 (5) 0 (0)
Domain total 10 (8) 0 (0)
Total 100 (77) 100 (16)Z 5 23.1, P , .01]. The total rate of scoring errors was
reduced from a mean of 1.5 to 0.8 following this correction.4. Discussion
Study 1 demonstrated that scoring and arithmetic errors
on cognitive screening tests are made in routine clinical
practice by specialist staff. Error rates are high with 22%
of ACE-IIIs containing error rates of 5 points or more. Sen-
tences, clock drawing, and animal fluency subtests showed
the highest error rates. Study 1 was limited in its ability to
capture administration error because it was not possible to
observe clinicians conducting the test. Study 2 assessed
administration of ACE-III and ACEmobile. Error rates
were significantly higher in the ACE-III group.
Both studies reveal that ACE-III, when used by appropri-
ately skilled individuals, is still prone to rater error. In study
2, the participants of the ACE-III group were provided with
time to familiarize themselves with the manual and were
able to refer to it during the assessment. In the context of a
challenging cognitive profile, with an examinee script that
tested areas known to be susceptible to error, administration
using ACE-III revealed large margins of error. In this
context, ACEmobile increased the accuracy of measurement
by a minimum of 85%. This increased to 93% accuracy
when a usability issue with the naming subtest was resolved.
The impact of these findings is relevant in numerous
contexts. In clinical and research settings, the value of a single
score in supporting diagnosis, disease staging, and prescrib-
ing is essential. In situations requiring serial assessment
(e.g., follow-up appointments), the ability to measure disease
progression and evaluate the effectiveness of medication is
dependent upon the accuracy of a screening tool to capture
change over time. The existence of an error rate of 10.3 points
(ranges 4–20) would potentially undermine a clinician’s abil-
ity to be confident in the reliability of the obtained score,
where a score of 82 suggests clinical impairment and error
impacts on clinical decision making. ACEmobile demon-
strates that a computer-supported approach, which is under-
pinned by a clear understanding of how the tool performs in
the hands of the user, can improve the accuracy of measure-
ment, even with a challenging score profile.
The method in this article is arguably both a model for
future development of existing or new tools and an invitation
for other cognitive assessments to be similarly evaluated.
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itively simple, with paper tools freely available to download.
It is feasible to consider that tools have been developed that
are intuitive to their authors yet complex and challenging to
those who try to use them in the real world. This is parti-
cularly pertinent in the context of increasing pressure on ser-
vices to see more patients with fewer resources and greater
reliance on staff with less training and experience in the
use of such tests. There is a need for human factors research
to be an integral part of the evaluation of current cognitive
assessment and design of future measures.
Undertaking this study highlighted some issues with both
the ACE-III and ACEmobile. Problems with sentences and
clock drawing highlighted in study 1 were communicated to
the developers of the ACE-III. The scoring criteria were sub-
sequently updated, and these changes were incorporated into
ACEmobile. It was also clear that ACEmobile did have some
inherent administration error and, after evaluation, it was
attributed to training failures. To address these, a training
video was made and has now been embedded into the App.
A limitation of the article is the use of skilled but not
specialist participants in study 2 insofar as the observed error
rate could have been an artifact of experience. Although this
is possible, it was felt this method was not outside of ecolog-
ical validity. The amount of training available to participants
was felt to reflect routine clinical practice. In addition, partic-
ipants in study 2 had ready and continued access to the
manual and replicated the observed error rates seen in study 1.
The delivery of this study highlighted the challenges of
scoringwhere subjective judgments are required, aswithvisuo-
spatial tests, particularly the cube.This emphasizes theneed for
further research to either better support scoring in ACEmobile
or to introduce less subjective assessment paradigms or more
automated scoring technologies (machine learning, etc.).
It is worth acknowledging that in study 2, ACEmobile
administration was supported by a training video, but an
equivalent was not provided for ACE-III. This adds an addi-
tional confound. However, this was intentional as the study
sought to create a context that simulated standard clinical
practice as closely as possible.
This study also has an implication for research where the
challenge of achieving high levels of interrater reliability
has been well documented. Inconsistent administration and
scoring between raters offer a major threat to the success of
clinical trials. Using automation, ACEmobile significantly
reduces the chance of interrater and intrarater error and offers
a potentially useful tool to support outcome research in the
field of dementia.
There are potential drawbacks of computerized assess-
ments. These include forgetting passwords, battery failures,
software failures, and loss of internet connection, which can
all threaten the utility of computerized tests. Any additional
value added by using a computerized test needs to beweighed
against the ease of the use of a paper-and-pencil test.
Finally, there is a need for further evaluation and vali-
dation of ACEmobile to ensure that the changes in datacollection described do not have impact on the ACE-III’s
ability to discriminate dementia and/or change the normative
data and established cutoffs.5. Summary
Administration, scoring, and reporting errors are
common in routine use of cognitive screening tools. ACE-
mobile is very effective at reducing errors when compared
with the standard paper-and-pen test. This is likely to offer
considerable value in clinical and research settings where
the ability to accurately measure cognition is a key compo-
nent of the diagnostic process or the success of a clinical trial
in demonstrating a treatment effect.
ACEmobile is currently provided as a free tool, with no re-
strictions for clinical use, available on iTunes and is already
registered for use in over 1100 clinical settings worldwide.
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1. Systematic review: The authors reviewed the literature
using traditional sources (e.g., PubMed), conference
proceedings and meeting abstracts. A small number
of citations highlight the importance of usability
research in the evaluation of medical devices (i.e.,
how a person interacts with the systems and technolo-
gies they use). Nonetheless, this promising approach
has hitherto been neglected in the validation of cogni-
tive tests.
2. Interpretation: Our findings reveal the nature and
extent of errors on a commonly used cognitive
screening tool in NHS memory clinics (ACE-III).
These same errors were largely overcome by a
computerized assessment (ACEmobile), designed
and evaluated using a human factors approach.
3. Future directions: The manuscript calls for the use of
human factors approaches in the comprehensive
evaluation of new and existing cognitive screening
tests (both traditional pen-and-paper and digital
assessment tools). In clinical and research contexts,
computerized cognitive tests have the potential to
dramatically reduce scoring errors.
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